Back to Market返回行情

BAX Baxter International Inc.

USHealthcare
$22.62+0.71%ClosedMarket Cap: $11.68B

As of 2026-07-10 16:00

Why BAX matters now

Baxter International Inc. (BAX) is a US stock in Healthcare. The latest InvestLog snapshot shows $22.62 with +0.71% on the session and $11.68B in market capitalization; recent performance reads 1-month +8.51% and YTD +4.08%.

The latest financial table shown here is Q1 2026, with revenue of $2.70B, net income of $-15.0M, and EPS of $-0.03. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield 7.0%.

The latest indexable market news headline is "Baxter to Host Second-Quarter 2026 Financial Results Conference Call for Investors" from Business Wire.

Additional event context on this page matters because analyst consensus is Hold with a median target of $20.00; recent insider activity includes Ampofo William A. II filing A-Award; recent congressional disclosure data includes Ro Khanna Purchase. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

PEG

P/B

1.70

P/S

0.91

EV/EBITDA

24.31

DCF Value

$-3.23

FCF Yield

7.0%

Div Yield

1.0%

Margins & Returns

Gross Margin

30.1%

Operating Margin

-2.7%

Net Margin

-9.7%

ROE

-16.4%

ROA

-5.5%

ROIC

-1.8%

Financials

PeriodRevenueNet IncomeEPS
Q1 2026$2.70B$-15.0M$-0.03
Q4 2025$2.97B$-1.13B$-2.16
FY 2025$11.24B$-957.0M$-1.75
Q3 2025$2.83B$-46.0M$-0.09

Analyst Ratings

Consensus

Hold

Target (Consensus)

$20.71

Target (Median)

$20.00

Target Range

$17.00 - $27.00

Strong Buy: 0Buy: 2Hold: 11Sell: 1Strong Sell: 0
CitigroupSell
2026-05-28
BarclaysOverweight
2026-05-04
Evercore ISI GroupOutperform
2026-04-06
CitigroupNeutral
2026-03-11
Goldman SachsNeutral
2026-02-17

Trading Activity

Insider Trades

Ampofo William A. IIdirector
Sell2026-05-07
Craig Jeffrey Adirector
Sell2026-05-07
McDonnell Michael R.director
Sell2026-05-07
Shafer David Brentdirector, other: Chair of the Board
Sell2026-05-07
MORRISON PATRICIAdirector
Sell2026-05-07

Congress Trades

Ro KhannaBuy
2026-06-11
Michael McCaulBuy
2026-04-10

Company Info

Sector

Healthcare

Industry

Medical - Instruments & Supplies

Country

US

Exchange

Beta

0.64

Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.